Zhang Financial LLC Has $2.81 Million Holdings in Zoetis Inc. (NYSE:ZTS)

Zhang Financial LLC decreased its holdings in Zoetis Inc. (NYSE:ZTS) by 11.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 17,239 shares of the company’s stock after selling 2,137 shares during the period. Zhang Financial LLC’s holdings in Zoetis were worth $2,809,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in ZTS. Darwin Wealth Management LLC acquired a new position in shares of Zoetis during the 3rd quarter worth approximately $31,000. First Personal Financial Services bought a new position in Zoetis during the third quarter worth $33,000. Capital Performance Advisors LLP acquired a new position in shares of Zoetis in the third quarter valued at $33,000. Dunhill Financial LLC raised its position in shares of Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares during the period. Finally, Quarry LP raised its position in shares of Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after purchasing an additional 153 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ZTS has been the topic of a number of research reports. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Leerink Partners started coverage on Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price on the stock. JPMorgan Chase & Co. lifted their price target on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. UBS Group assumed coverage on Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target for the company. Finally, Stifel Nicolaus dropped their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Zoetis has an average rating of “Buy” and a consensus target price of $211.89.

Zoetis Stock Performance

NYSE:ZTS opened at $166.01 on Monday. The company has a market cap of $74.90 billion, a price-to-earnings ratio of 31.20, a PEG ratio of 2.51 and a beta of 0.89. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.53. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The stock has a fifty day moving average price of $170.93 and a 200-day moving average price of $179.98.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.46 by $0.12. The business had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. Zoetis’s revenue was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.36 earnings per share. As a group, equities analysts anticipate that Zoetis Inc. will post 5.91 EPS for the current fiscal year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be given a dividend of $0.50 per share. This is an increase from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 annualized dividend and a yield of 1.20%. The ex-dividend date is Tuesday, January 21st. Zoetis’s payout ratio is currently 32.52%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.